Advertisement
Person › Details
Christopher F. (Chris) Brinzey (Westwicke Partners LLC)
Brinzey, Christopher F. (Chris) (Westwicke Partners 201703)
Organisation | Westwicke Partners LLC | |
Today | Westwicke, an ICR Company | |
Group | ICR (Group) | |
Product | public relations / investor relations / marcom (services) | |
Product 2 | LIFE SCIENCES | |
CRISPR Therapeutics AG. (3/2/17). "Press Release: CRISPR Therapeutics to Present at the Annual Barclays Global Healthcare Conference". Basel & Cambridge, MA.
CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into transformative medicines, today announced that Rodger Novak, M.D., Chief Executive Officer and Founder of CRISPR Therapeutics, will present at the Annual Barclays Global Healthcare Conference on Thursday, March 16th at the Loews Miami Beach Hotel, Miami, FL.
Event: Annual Barclays Global Healthcare Conference
Date: Thursday, March 16th
Time: 8:00 AM ET
A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors & Media section of the Company's website at www.crisprtx.com.
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR / Cas9 gene-editing platform. CRISPR / Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The Company's multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR / Cas9 patent estate for human therapeutic use was licensed from the Company's scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics is headquartered in Basel, Switzerland with its R&D operations based in Cambridge, Massachusetts. For more information, please visit www.crisprtx.com.
MEDIA CONTACTS:
Jennifer Paganelli
W2O Group for CRISPR
347-658-8290
jpaganelli@w2ogroup.com
INVESTOR CONTACT:
Chris Brinzey
Westwicke Partners for CRISPR
339-970-2843
chris.brinzey@westwicke.com
Record changed: 2023-05-23 |
Advertisement
More documents for Christopher F. (Chris) Brinzey
- [1] AvroBio, Inc.. (5/22/23). "Press Release: AvroBio Announces Agreement to Sell Cystinosis Gene Therapy Program for $87.5 Million". Cambridge, MA....
- [2] CRISPR Therapeutics AG. (8/7/18). "Press Release: CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2018 Financial Results". Zug & Cambridge, MA....
- [3] Replimune Group Inc.. (7/19/18). "Press Release: Replimune Announces Pricing of Initial Public Offering". Woburn, MA....
- [4] CRISPR Therapeutics AG. (5/30/18). "Press Release: CRISPR Therapeutics and Vertex Provide Update on FDA Review of Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease". Boston, MA, Zug & Cambridge, MA....
- [5] Faron Pharmaceuticals Oy. (2/5/18). "Press Release: Faron Establishes Second Traumakine Manufacturing Site". Turku....
- [6] CRISPR Therapeutics AG. (1/4/18). "Press Release: CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares". Zug & Cambridge, MA....
- [7] CRISPR Therapeutics AG. (1/3/18). "Press Release: CRISPR Therapeutics Announces Proposed Public Offering of Common Shares". Zug & Cambridge, MA....
- [8] CRISPR Therapeutics AG. (11/28/17). "Press Release: CRISPR Therapeutics to Participate in Upcoming Investor Conferences". Zug & Cambridge, MA....
- [9] CRISPR Therapeutics AG. (10/4/17). "Press Release: CRISPR Therapeutics to Present at Investor Conferences in October". Zug & Cambridge, MA....
- [10] NuCana plc. (10/2/17). "Press Release: NuCana plc Announces Closing of Initial Public Offering of ADSs and Exercise of Underwriters’ Option to Purchase Additional ADSs". Edinburgh....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top